Privia Health Group Future Growth
Future criteria checks 3/6
Privia Health Group is forecast to grow earnings and revenue by 31.9% and 8.8% per annum respectively. EPS is expected to grow by 29.8% per annum. Return on equity is forecast to be 6.4% in 3 years.
Key information
31.9%
Earnings growth rate
29.76%
EPS growth rate
| Healthcare earnings growth | 18.9% |
| Revenue growth rate | 8.8% |
| Future return on equity | 6.44% |
| Analyst coverage | Good |
| Last updated | 05 Jun 2026 |
Recent future growth updates
Recent updates
Narrative Update • Jun 04
PRVA: New Jersey Expansion And Q4 Execution Will Support Future EBITDA
Narrative update: Privia Health Group The analyst price target for Privia Health Group has been trimmed by $1 to reflect a slightly lower fair value estimate of $31.60, as analysts factor in updated assumptions on discount rates, revenue growth, profit margins, and sector risks highlighted in recent research. Analyst Commentary Recent Street research on Privia Health Group reflects a mix of optimism and caution, with several firms fine-tuning price targets after recent quarterly results and sector wide adjustments.Analysis Article • May 14
Privia Health Group's (NASDAQ:PRVA) Earnings May Just Be The Starting Point
Even though Privia Health Group, Inc. ( NASDAQ:PRVA ) posted strong earnings, investors appeared to be underwhelmed. We...Narrative Update • Apr 26
PRVA: Fee For Service Timing And Q4 Execution Will Support EBITDA
Analysts now set Privia Health Group's fair value at $31.80, a small move from $31.75. This reflects a mix of recent price target revisions that factor in solid Q4 results, updated estimates and ongoing discussions around fee for service collection trends.Narrative Update • Apr 11
PRVA: Payor Agnostic Enablement And Collections Timing Execution Will Support EBITDA
Privia Health Group's updated fair value estimate edges to $31.75 from $31.95 as analysts balance slightly softer embedded revenue growth assumptions with a modestly higher profit margin outlook and a similar future P/E profile, following a mix of recent price target raises and cuts across the Street. Analyst Commentary Recent Street research around Privia Health Group shows a mixed but generally constructive tone, with several price target raises offset by a couple of modest trims.Narrative Update • Mar 28
PRVA: Payor Agnostic Physician Enablement And Claims Timing Clarity Will Support EBITDA
The fair value estimate for Privia Health Group has been nudged higher from $31.85 to $31.95. This reflects analysts' updated targets after recent research cited a solid Q4 report, management commentary on claims timing, renewed coverage, and several price target revisions in the low to mid $30s range.Narrative Update • Mar 13
PRVA: Payor Agnostic Network Expansion And Value Based Care Adoption Will Support EBITDA
Analysts have nudged their average price target for Privia Health Group higher, with our fair value estimate moving from $31.37 to $31.85 as they factor in recent price target revisions and updated views on the company's growth and profitability profile. Analyst Commentary Recent Street research on Privia Health Group reflects a mix of optimism around growth and execution, alongside some caution on valuation and near term business trends.Narrative Update • Feb 27
PRVA: Payor Agnostic Physician Network Expansion Will Support Future EBITDA Upside
Narrative Update Analysts recently nudged their average price target for Privia Health Group up by about $1 to around $31, citing what they described as an "impressive" Q4, ongoing business momentum, and expectations that physician network expansion and acquisitions could support growth and make the shares look inexpensive relative to projected EBITDA and future P/E levels. Analyst Commentary Recent research updates on Privia Health Group tilt clearly positive, with price targets clustering around the low US$30s and commentary focused on execution in physician enablement, earnings power, and how the shares are valued against projected EBITDA and P/E metrics.Narrative Update • Feb 13
PRVA: Payor Agnostic Physician Network Expansion Will Drive Value Based Care Upside
Analysts have maintained their $31 price target on Privia Health Group, pointing to the company’s role in physician enablement and expectations that its payor agnostic model and expanding physician network can support continued growth in value based care through 2026 to 2027. Analyst Commentary Analysts looking at Privia Health Group are weighing the company’s position in physician enablement against execution risks around scaling its model and sustaining value based care adoption through 2026 to 2027.Narrative Update • Jan 27
PRVA: Physician Enablement Platform Will Benefit From Expanding Payor Agnostic Physician Network
Analysts have updated their price target on Privia Health Group to US$31.25 from US$31.26, reflecting continued confidence in the company as a leading physician enablement platform as it grows its physician network and fee-based collections within a payor-agnostic model. Analyst Commentary Bullish Takeaways Bullish analysts view Privia Health as a key play in physician enablement, which they see as an area with meaningful room for adoption as technology and healthcare utilization continue to intersect.Analysis Article • Jan 22
Take Care Before Diving Into The Deep End On Privia Health Group, Inc. (NASDAQ:PRVA)
It's not a stretch to say that Privia Health Group, Inc.'s ( NASDAQ:PRVA ) price-to-sales (or "P/S") ratio of 1.4x...Narrative Update • Jan 11
PRVA: Physician Enablement And Fee-Based Collections Will Drive Future Earnings Upside
Analysts have modestly refined their assumptions on growth, margins, and future P/E for Privia Health, leading to a refreshed price target near US$31. This updated view leans on the company’s role in physician enablement and a payor agnostic model, as coverage resumes with a positive perspective on its long term network expansion and fee based collections opportunity.Narrative Update • Dec 16
PRVA: Future Shared Savings Results Will Drive Earnings Upside Through 2025
Analysts have nudged their price target on Privia Health Group slightly higher to approximately $31.26 per share from about $31.11, reflecting modest improvements in projected profitability and long term earnings multiples, despite largely unchanged growth and discount rate assumptions. What's in the News Raised full year 2025 GAAP revenue guidance to a range of $2,050 million to $2,100 million, up from the prior outlook of $1,800 million to $1,900 million (company guidance) Management signaled increased confidence in the growth trajectory for 2025, citing stronger than previously anticipated top line performance embedded in the higher revenue range (company guidance) The guidance revision suggests improved operating momentum heading into 2025, with investors focusing on execution against the upgraded revenue targets (company guidance) Valuation Changes Fair Value Estimate has risen slightly to approximately $31.26 from about $31.11 per share, reflecting modest upward revisions to profitability assumptions.Narrative Update • Nov 27
PRVA: Future Shared Savings Results Will Drive Earnings Upside Through 2025
Privia Health Group's analyst fair value estimate has increased slightly to $31.11 from $30.89, as analysts cite improved revenue growth projections and stronger 2025 EBITDA guidance following favorable Medicare Shared Savings Program results. Analyst Commentary Analysts provided updated perspectives on Privia Health Group following recent announcements and improved financial guidance.Analysis Article • Nov 24
Be Wary Of Privia Health Group (NASDAQ:PRVA) And Its Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...Narrative Update • Nov 10
PRVA: Future Shared Savings Performance Will Support Profitability And Earnings Momentum
Analysts have raised their price target for Privia Health Group to approximately $30.89 from $30.15 per share, citing improved EBITDA guidance as a result of continued strong performance in shared savings programs. Analyst Commentary Recent analyst opinions reflect both confidence and caution regarding Privia Health Group's prospects.Analysis Article • Aug 15
We Think Privia Health Group's (NASDAQ:PRVA) Healthy Earnings Might Be Conservative
NasdaqGS:PRVA 1 Year Share Price vs Fair Value Explore Privia Health Group's Fair Values from the Community and select...Seeking Alpha • Jul 28
Privia Health: A Lesson In Cash Flow Timing, Operating Margins, And Returns On Capital
Summary Privia Health's asset-light, high turnover model is hampered by persistently thin margins, negative economic profit, and a lengthy cash conversion cycle. Despite revenue growth and onboarding new physician groups, operating leverage remains elusive, with working capital needs offsetting gains and free cash flow remaining erratic. Valuation is stretched at 66x forward EBIT, with market expectations for sustained double-digit growth appearing unrealistic, given historical performance and industry base rates. I reiterate a hold rating, seeing fair value at ~$16/share, with high risk of multiple contractions and limited upside under current business economics. Read the full article on Seeking AlphaAnalysis Article • Jul 28
It's A Story Of Risk Vs Reward With Privia Health Group, Inc. (NASDAQ:PRVA)
There wouldn't be many who think Privia Health Group, Inc.'s ( NASDAQ:PRVA ) price-to-sales (or "P/S") ratio of 1.3x is...Analysis Article • Apr 23
Privia Health Group (NASDAQ:PRVA) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Feb 05
Is There An Opportunity With Privia Health Group, Inc.'s (NASDAQ:PRVA) 48% Undervaluation?
Key Insights Privia Health Group's estimated fair value is US$44.59 based on 2 Stage Free Cash Flow to Equity Privia...Analysis Article • Nov 08
After Leaping 32% Privia Health Group, Inc. (NASDAQ:PRVA) Shares Are Not Flying Under The Radar
Privia Health Group, Inc. ( NASDAQ:PRVA ) shareholders would be excited to see that the share price has had a great...Analysis Article • Nov 04
There Are Reasons To Feel Uneasy About Privia Health Group's (NASDAQ:PRVA) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Analysis Article • Sep 12
It's A Story Of Risk Vs Reward With Privia Health Group, Inc. (NASDAQ:PRVA)
It's not a stretch to say that Privia Health Group, Inc.'s ( NASDAQ:PRVA ) price-to-sales (or "P/S") ratio of 1.3x...
New Narrative • Sep 10
Tactical Expansions And Value-Based Care Drive Optimistic Growth In Healthcare Sector
Privia Health's strategy focuses on market penetration and provider network expansion to fuel revenue growth, alongside restructuring contracts for better margins.Analysis Article • Aug 16
There May Be Reason For Hope In Privia Health Group's (NASDAQ:PRVA) Disappointing Earnings
The market was pleased with the recent earnings report from Privia Health Group, Inc. ( NASDAQ:PRVA ), despite the...Analysis Article • Jul 12
Some Investors May Be Worried About Privia Health Group's (NASDAQ:PRVA) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Analysis Article • Jun 11
Privia Health Group, Inc.'s (NASDAQ:PRVA) Subdued P/S Might Signal An Opportunity
There wouldn't be many who think Privia Health Group, Inc.'s ( NASDAQ:PRVA ) price-to-sales (or "P/S") ratio of 1.2x is...Seeking Alpha • May 22
Privia Health: Key Lessons Learned (Rating Downgrade)
Summary Shares of Privia Health Group have declined 37% since the last report, prompting a reevaluation of our investment thesis. PRVA has struggled to earn a decent rate of return on its capital, with a return of only 2.6% in the past year. Valuations are stretched, with the company trading at 24x forward earnings and 80x forward EBIT. Read the full article on Seeking AlphaAnalysis Article • Mar 03
Analysts Just Slashed Their Privia Health Group, Inc. (NASDAQ:PRVA) EPS Numbers
Today is shaping up negative for Privia Health Group, Inc. ( NASDAQ:PRVA ) shareholders, with the analysts delivering a...Analysis Article • Feb 27
The Price Is Right For Privia Health Group, Inc. (NASDAQ:PRVA)
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Analysis Article • Jan 31
There Are Reasons To Feel Uneasy About Privia Health Group's (NASDAQ:PRVA) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 2,954 | 85 | 173 | 178 | 7 |
| 12/31/2027 | 2,666 | 57 | 148 | 154 | 16 |
| 12/31/2026 | 2,427 | 35 | 129 | 132 | 16 |
| 3/31/2026 | 2,247 | 22 | 138 | 138 | N/A |
| 12/31/2025 | 2,123 | 23 | 163 | 163 | N/A |
| 9/30/2025 | 2,043 | 18 | 111 | 111 | N/A |
| 6/30/2025 | 1,900 | 15 | 92 | 92 | N/A |
| 3/31/2025 | 1,801 | 16 | 118 | 118 | N/A |
| 12/31/2024 | 1,736 | 14 | 109 | 109 | N/A |
| 9/30/2024 | 1,716 | 13 | 99 | 99 | N/A |
| 6/30/2024 | 1,696 | 15 | 88 | 88 | N/A |
| 3/31/2024 | 1,687 | 19 | 61 | 61 | N/A |
| 12/31/2023 | 1,658 | 23 | 81 | 81 | N/A |
| 9/30/2023 | 1,581 | 38 | 46 | 46 | N/A |
| 6/30/2023 | 1,507 | 34 | 39 | 40 | N/A |
| 3/31/2023 | 1,429 | 16 | 39 | 39 | N/A |
| 12/31/2022 | 1,357 | -9 | 47 | 47 | N/A |
| 9/30/2022 | 1,268 | -38 | 5 | 6 | N/A |
| 6/30/2022 | 1,176 | -49 | 52 | 52 | N/A |
| 3/31/2022 | 1,066 | -211 | 52 | 52 | N/A |
| 12/31/2021 | 966 | -188 | 55 | 55 | N/A |
| 9/30/2021 | 905 | -172 | 64 | 64 | N/A |
| 6/30/2021 | 860 | -147 | 37 | 37 | N/A |
| 3/31/2021 | 818 | 31 | 43 | 43 | N/A |
| 12/31/2020 | 817 | 31 | 39 | 39 | N/A |
| 12/31/2019 | 786 | 8 | N/A | 24 | N/A |
| 12/31/2018 | 658 | -3 | N/A | 5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRVA's forecast earnings growth (31.9% per year) is above the savings rate (3.5%).
Earnings vs Market: PRVA's earnings (31.9% per year) are forecast to grow faster than the US market (16.9% per year).
High Growth Earnings: PRVA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PRVA's revenue (8.8% per year) is forecast to grow slower than the US market (11.8% per year).
High Growth Revenue: PRVA's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRVA's Return on Equity is forecast to be low in 3 years time (6.4%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 22:09 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Privia Health Group, Inc. is covered by 32 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hua Ha | Baird |
| Andrew Mok | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |